Tyra Biosciences, Inc. (TYRA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-14
NASDAQHealth CareBiotechnologySnapshot 2026-09-14
Research Workspace
Put TYRA beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Report initial three-month complete response data by August 2026: Data reported 2026-09-09 vs target 2026-08-31.
View ThesisThis stock is highly volatile — it swings about 2% on a typical day and fell roughly 44% in its worst 12-month stretch.
View RiskTYRA's growth depends on advancing its dabogratinib clinical strategy and reporting initial data. Revenue performance has been weak, with the latest earnings showing a miss. The stock trades at a premium, with no earnings yield to assess. This premium must be justified by strong future performance. A recent drop of 21% suggests the market is repricing the thesis. The primary risk is the potential for guidance cuts, with a 43% chance of missing expectations. Peer performance in the healthcare sector could also impact TYRA's trajectory. Peer multiples imply a price about 21% below where it trades. This read is provisional.
Trailing returns as of 2026-09-14. TYRA is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 15 analysts currently covering TYRA (as of Sep 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare TYRA with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| TYRA Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 0 valuation methods, at three horizons. As of 2026-09-14. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put TYRA next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Threatens: Maintain financial runway into second half of 2028
Dilution may impact financial runway into 2028.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-14. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.

Threatens: Advance dabogratinib 3x3 clinical strategy
Disappointing data impacts advancement of dabogratinib strategy.

Threatens: Report initial clinical data for SURF302 in 2026
Caution on data readouts may delay clinical progress.

SURF-302 skepticism could impact product confidence.